Ad Hoc Announcement Pursuant to 5 WpHG: Carl Zei Meditec invests in innovative radirapy solution for wet age-related macular degeneration

JENA/Germany, 22.12.2014.

Carl Zeiss Meditec Inc., a 100%-owned subsidiary of Carl Zeiss Meditec AG (ISIN: DE0005313704) has signed a collaboration agreement with Oraya Therapeutics Inc., Newark, USA (Oraya). Over the past few years, Oraya has developed the novel low energy radiation therapy Oraya Therapy for wet age-related macular degeneration (wet AMD) and introduced it to the market.

Under the terms of the agreement, Carl Zeiss Meditec will provide funding to Oraya for the implementation of its growth strategy over a period of up to two years and in turn receive rights for a participation in the company reaching up to a majority stake after two years. The amount of the funding provided to Oraya has not been disclosed. Carl Zeiss Meditec expects this investment to further strengthen its role as global innovation leader in ophthalmology as well as its existing portfolio of solutions for diagnosis and therapy of eye diseases.

Jann Gerrit Ohlendorf

Director Corporate Communications

Carl Zeiss Meditec AG

Phone: +49 3641 220-331

Fax: +49 3641 220-332

press.meditec@zeiss.com

Sebastian Frericks

Investor Relations

Carl Zeiss Meditec AG

Phone: +49 3641 220-116

investors.meditec@zeiss.com

Brief profile

Carl Zeiss Meditec AG (ISIN: DE 0005313704), which is listed on TecDAX of the German stock exchange, is one of the world's leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. It provides complete packages of solutions for the diagnosis and treatment of eye diseases, including implants and consumable materials. The Company creates innovative visualization solutions in the field of microsurgery. The medical technology portfolio of Carl Zeiss Meditec is rounded off by promising, future-oriented technologies such as intraoperative radiotherapy. With almost 3,000 employees, the Group generated revenue of 909 million in financial year 2013/2014 (to 30 September).

The head office of Carl Zeiss Meditec is in Jena, Germany. The Company has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Research and Development (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the presence in these rapidly developing economies. Around 35 percent of Carl Zeiss Meditec shares are in free float. The remaining approx. 65 percent are held by Carl Zeiss AG, one of the world's leading groups in the optical and optoelectronic industries.

ZEISS offers innovative solutions for the future-oriented markets Industrial Solutions, Research Solutions, Medical Technology and Consumer Optics. Carl Zeiss AG, Oberkochen, is wholly owned by the Carl Zeiss Foundation.

For more information visit:

www.meditec.zeiss.com

Number: 0155-2014-ENG OP

Number of Words: 161

Number of Characters: 1022

LINK:	http://applications.zeiss.com/C1256A770030BCE0/WebViewTopNewsAllE/3184...
	See more stories from zeiss

Most recent headlines